Evaluation of Broadband Light Treatment Protocol for Pigmented Skin Lesions - A Comparative Study
NCT ID: NCT05662592
Last Updated: 2023-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
3 participants
INTERVENTIONAL
2022-10-01
2023-06-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Arm
Broadband light treatment will be provided on pigmented skin lesions
Broadband Light
Broadband Light device will be used for treatment of pigmented skin lesions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Broadband Light
Broadband Light device will be used for treatment of pigmented skin lesions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Fitzpatrick skin type I-IV
3. Has visible signs of moderate to severe skin pigmentation
4. Willing to not use any other procedure(s) in the treatment area during the study, such as laser- or light-based treatment, non-light-based device treatment such as radiofrequency or ultrasound, injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler, chemical peel, or surgical procedure
5. Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study. (applicable to female subjects only)
6. Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treatment area every day for the duration of the study, including the follow-up period
7. Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes
8. Subject must agree to not make any changes in their skin regimen for the duration of the study, including the follow-up period
9. Subject must be able to read, understand and sign Informed Consent Form
10. Must be willing to adhere to the treatment and follow-up schedule and post-treatment care instructions
Exclusion Criteria
2. Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study.
3. Any type of prior cosmetic treatment to the target area within 3 months of study participation, such as laser or light-based procedures or surgery.
4. Prior injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler in the target area within 1 week of study participation.
5. History of malignant tumors in the target area.
6. Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles.
7. Pregnant and/or breastfeeding (applicable to female subjects only)
8. Having an infection, dermatitis or a rash in the treatment area.
9. Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
10. Suffering from coagulation disorders or taking prescription anticoagulation medications.
11. History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
12. History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
13. History of vitiligo, eczema, or psoriasis.
14. History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
15. History of seizure disorders due to light.
16. Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
17. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
18. History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.
19. History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
20. Systemic use of retinoid, such as isotretinoin, or corticosteroid, as applicable, within 6 months of study participation.
21. Topical use of retinoid, such as isotretinoin, corticosteroid or hydroquinone on the target area within 1 month of participation.
22. Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
23. Excessively tanned in areas to be treated, or unable/unlikely to refrain from tanning during the study (for example, subject's occupation requires regular sun exposure).
24. Current smoker or history of smoking within 6 months of study participation.
25. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sciton
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Jersey Plastic Surgery
Montclair, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SBBLCIP004
Identifier Type: -
Identifier Source: org_study_id